LNF2102 / Lunan Pharma - LARVOL DELTA

LNF2102: A novel FGFR2b-targeted monoclonal antibody with mitigated ocular toxicity in preclinical studies (ESMO 2025) - "Notably, in comparison with bemarituzumab, LNF2102 demonstrated a weaker ability to block FGF10. Legal entity responsible for the study Lunan Pharmaceutical Group Co., Ltd. Funding Lunan Pharmaceutical Group Co., Ltd."

Preclinical • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Gastric Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • FGF10 • FGF7 • HER-2